HIMUKA AM PHARMA CORP.

HOME            About            News & Topics            Adrenomedullin

 
 


Himuka AM Pharma Corp. is a venture company originating from University of Miyazaki.

We develop drug seeds with a strong focus on derivatives of a bioactive peptide adrenomedullin (AM) which was discovered at University of Miyazaki (formerly Miyazaki Medical College). Our drug seeds will make significant contributions to resolve unmet medical needs.

 

English        Japanese

Apr. 15, 2018    Featured on Journal of Industry-Academia-Government Collaboration.


Mar. 30, 2018    Completed second closing of an equity financing.


Dec. 28, 2017    Completed first closing of an equity financing.


Apr. 24, 2017    Selected for “Support Program for Orphan drug prior to the Designation” by AMED.


Feb. 13, 2017    Certified as a “Venture company originating from University of Miyazaki”.


Feb. 1, 2017    Established Himuka AM Pharma Corp.

News & Topics